Empagliflozin-pretreated BMSC exosomes attenuate myocardial ischemia-reperfusion injury by enhancing atad3a/pink1-dependent mitophagy.

ABSTRACT:

Background and objectives

Mounting evidence demonstrates that exosomes derived from mesenchymal stem cells (MSCs) can mitigate myocardial ischemia-reperfusion injury (MIRI). However, the therapeutic potential of untreated MSC-derived exosomes remains limited. Here, we investigate whether exosomes derived from sodium-glucose co-transporter 2 inhibitor (SGLT2i)-pretreated MSCs exhibit enhanced cardioprotective effects against MIRI and elucidate the underlying mechanisms.

Methods and results

Mouse bone marrow-derived MSCs (BMSCs) were pretreated with the SGLT2 inhibitor empagliflozin (EMPA), and the secreted exosomes (EMPA-EXO) were isolated. Primary neonatal cardiomyocytes were co-cultured with EMPA-EXO or untreated exosomes (EXO) for 24 h before hypoxia-reoxygenation (H/R) in

SUBMITTER: Jing Y 

PROVIDER: S-EPMC12573846 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature